Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
用于治疗胰腺癌的一流 NDUFS7 拮抗剂的临床前开发
基本信息
- 批准号:10684845
- 负责人:
- 金额:$ 46.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-16 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAntimycin ABioenergeticsBiomassBromouridine sequencingCancer cell lineCell HypoxiaCell LineCellsClinicalClinical ResearchDNA Repair GeneDataDependenceDiseaseDoseDown-RegulationDrug CombinationsDrug Delivery SystemsDrug or chemical Tissue DistributionDrug resistanceEquilibriumFDA approvedFutureGenerationsGenesGenetically Engineered MouseGlycolysisGrowthHumanImageImmune checkpoint inhibitorKRAS2 geneLeadMalignant neoplasm of pancreasMass Spectrum AnalysisMediatingMetforminMissionMitochondriaModelingMusMutateNeoplasm MetastasisNull LymphocytesOligomycinsOncologyOralOrganOxidation-ReductionOxidative PhosphorylationOxygen ConsumptionPTEN genePancreatic Ductal AdenocarcinomaPatientsPharmaceutical PreparationsPhosphorylation InhibitionPlayProductionPrognosisProliferatingProteomicsPublic HealthResistanceRoleRotenoneSWI/SNF Family ComplexSafetySeriesTestingTherapeuticToxic effectTransgenic MiceTumor TissueTumor-Associated ProcessTyrosine Kinase InhibitorUnited States National Institutes of HealthWorkanalogantagonistcancer cellcancer stem cellchemotherapyclinical candidateclinical developmentcohortcytotoxicitydesignefficacy evaluationexome sequencinggemcitabinein vivoinhibitorinnovationlead optimizationmultiple omicsnanomolarnovelnovel therapeuticsoverexpressionpancreatic cancer cellspancreatic ductal adenocarcinoma cellpancreatic neoplasmpatient subsetspharmacokinetics and pharmacodynamicspharmacologicpreclinical developmentresponsestandard of caresynergismthree dimensional cell culturetooltranscriptome sequencingtumor initiationtumor progression
项目摘要
Oxidative phosphorylation (OXPHOS) plays an important role in mitochondria function by mediating
bioenergetics, biomass production, and redox balance, all essential processes for tumor progression,
metastasis, and survival. Thus, targeting OXPHOS holds great promise to treat PDAC. Metformin, a clinically
used OXPHOS inhibitor, has demonstrated increased survival in PDAC patients, suggesting that OXPHOS
inhibitors can safely be used to treat PDAC. A clearer picture is now emerging on the essential role of OXPHOS
in PDAC progression. For example, overexpression of OXPHOS genes correlates with poor prognosis in PDAC
patients, and suppression of mitochondrial oxygen consumption significantly retards PDAC progression. Drug
resistant PDAC cells ablated in KRAS are heavily dependent on OXPHOS and are sensitive to OXPHOS
inhibition. Pancreatic-tumor-initiating cells also show strong reliance on OXPHOS. Importantly, OXPHOS
inhibitors are synergistic with gemcitabine specifically in cells with high levels of OXPHOS-related genes.
Unfortunately, metformin has low potency and poor selectivity. Other classic OXPHOS inhibitors including
rotenone, antimycin A, and oligomycin, lack selectivity. We recently designed a series of highly potent OXPHOS
inhibitors (DX2-201 to DX3-236). Our ADMET-guided lead optimization campaign generated over 200 novel
analogues that led to the discovery of orally active OXPHOS inhibitors with nanomolar potency, acceptable
toxicity, and reasonable organ distributions to advance into clinical development. We profiled a set of 105 cancer
cell lines for their anti-proliferative response to DX analogues and found that our compounds profoundly inhibit
the proliferation of 5 out of 7 PDAC cell lines. Through the generation of drug resistance clones, followed by
whole exome sequencing, we identified NDUFS7 as the direct target of our lead compound DX2-201 in 6/6
clones. Our integrated multi-omics (RNA-seq, Bru-seq and mass spectrometry-based proteomics) studies
revealed down-regulation of DNA repair genes upon DX treatment. Our DX compounds also show significant
synergism with standard-of-care chemotherapy and several FDA-approved drugs. We hypothesize that
OXPHOS inhibitors will provide therapeutic benefit to PDAC patients, overcome drug resistance, and could be
safely and efficaciously combined with various drugs including immune checkpoint inhibitors. We will test this
hypothesis through the following specific aims: Aim 1. To assess cytotoxicity of top 5 compounds as single agent
and in combination with standard chemotherapy as well as several early-stage clinical candidates in a large
panel of mouse and human PDAC cell lines. Aim 2. To perform MTD, full PK/PD studies, and to determine tissue
distribution and accumulation of top 5 compounds in mice. Aim 3. To determine the in vivo efficacy of top 5
compounds as single agents and in combination with standard-of-care drug(s) from Aim 1 in orthotopic and
GEMM models of KRAS driven pancreatic cancer.
氧化磷酸化(OXPHOS)通过介导线粒体的功能,
生物能量学、生物量产生和氧化还原平衡,所有肿瘤进展的基本过程,
转移和存活。因此,靶向OXPHOS具有治疗PDAC的巨大希望。Metabolism,临床上
使用OXPHOS抑制剂,已证明PDAC患者的生存率增加,表明OXPHOS
抑制剂可以安全地用于治疗PDAC。现在,对OXPHOS的重要作用有了更清楚的认识
PDAC进展。例如,OXPHOS基因的过表达与PDAC的不良预后相关,
患者,并且抑制线粒体氧消耗显著延缓PDAC进展。药物
在KRAS中消融的耐药PDAC细胞严重依赖于OXPHOS,并且对OXPHOS敏感
抑制作用胰腺肿瘤起始细胞也显示出对OXPHOS的强烈依赖。重要的是,OXPHOS
抑制剂与吉西他滨具有协同作用,特别是在具有高水平OXPHOS相关基因的细胞中。
不幸的是,二甲双胍的效力低,选择性差。其他经典的OXPHOS抑制剂包括
鱼藤酮、抗霉素A和寡霉素缺乏选择性。我们最近设计了一系列高效的OXPHOS
抑制剂(DX2 - 201至DX3 - 236)。我们的ADMET引导的潜在客户优化活动产生了200多个新的
导致发现具有纳摩尔效力的口服活性OXPHOS抑制剂的类似物,
毒性和合理的器官分布,以推进临床开发。我们分析了一组105个癌症
细胞系对DX类似物的抗增殖反应,发现我们的化合物深刻地抑制了
7个PDAC细胞系中有5个细胞增殖。通过产生抗药性克隆,
通过全外显子组测序,我们在6/6中将NDUFS7鉴定为我们的先导化合物DX2 - 201的直接靶点。
克隆我们的综合多组学(RNA-seq,Bru-seq和基于质谱的蛋白质组学)研究
揭示了DX治疗后DNA修复基因的下调。我们的DX化合物还显示出显著的
与标准化疗和几种FDA批准的药物协同作用。我们假设
OXPHOS抑制剂将为PDAC患者提供治疗益处,克服耐药性,并且可以用于
安全有效地与包括免疫检查点抑制剂在内的各种药物联用。我们将测试这个
假设通过以下具体目标:目标1。评估前5种化合物作为单药的细胞毒性
并与标准化疗以及几种早期临床候选药物联合使用,
一组小鼠和人PDAC细胞系。目标二。进行MTD、完整PK/PD研究,并测定组织
前5种化合物在小鼠体内的分布和蓄积。目标3。确定前5名的体内功效
作为单一药剂的化合物和与来自目标1的标准护理药物的组合,
KRAS驱动的胰腺癌的GEMM模型。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer.
- DOI:10.1021/acs.jmedchem.2c01769
- 发表时间:2023-01
- 期刊:
- 影响因子:7.3
- 作者:Joyeeta Roy;A. Kyani;Maha Hanafi;Yibin Xu;J. Takyi-Williams;Duxin Sun;E. E. A. Osman-E.;N. Neamati
- 通讯作者:Joyeeta Roy;A. Kyani;Maha Hanafi;Yibin Xu;J. Takyi-Williams;Duxin Sun;E. E. A. Osman-E.;N. Neamati
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NOURI NEAMATI其他文献
NOURI NEAMATI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NOURI NEAMATI', 18)}}的其他基金
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
首创的结直肠癌 GSTO1 降解剂的临床前开发
- 批准号:
10675586 - 财政年份:2022
- 资助金额:
$ 46.36万 - 项目类别:
gp130 as a novel therapeutic target in ovarian cancer
gp130作为卵巢癌的新治疗靶点
- 批准号:
8797755 - 财政年份:2015
- 资助金额:
$ 46.36万 - 项目类别:
gp130 as a novel therapeutic target in ovarian cancer
gp130作为卵巢癌的新治疗靶点
- 批准号:
8994723 - 财政年份:2015
- 资助金额:
$ 46.36万 - 项目类别:
gp130 as a novel therapeutic target in ovarian cancer
gp130作为卵巢癌的新治疗靶点
- 批准号:
9903250 - 财政年份:2015
- 资助金额:
$ 46.36万 - 项目类别:
High Throughput Screen for Myotonic Dystrophy Type 1
1 型强直性肌营养不良的高通量筛查
- 批准号:
8209483 - 财政年份:2011
- 资助金额:
$ 46.36万 - 项目类别:
Inhibition of HIV-1 Integrase-LEDGF/P75 Interactions
HIV-1 整合酶-LEDGF/P75 相互作用的抑制
- 批准号:
7897668 - 财政年份:2009
- 资助金额:
$ 46.36万 - 项目类别:
相似海外基金
Study on structure of cytochrome b using antimycin A-resistant mutants.
利用抗霉素A突变体研究细胞色素b的结构。
- 批准号:
06660132 - 财政年份:1994
- 资助金额:
$ 46.36万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)